CCL27 and neoplasm: An alternate mouse model of ILC (Keratin14-cre;Cdh1Flox/Flox;Trp53Flox/Flox) was used to demonstrate temporary therapeutic benefit of the mTOR inhibition (AZD8055), leading to pathway suppression and tumour response that was mediated, at least in part, by the adaptive immune response [121].